Sironax

The company's business model is centered on the discovery, in-house development, and clinical progression of novel drug candidates. Sironax has secured substantial financial backing, raising over $300 million to date, including a significant $200 million Series B financing round in August 2022. This funding is being used to advance its clinical pipeline and expand research and development operations. The company's strategy also includes strategic partnerships, such as a July 2025 agreement with Novartis, granting an exclusive option to acquire Sironax's Brain Delivery Module (BDM) platform, a technology designed to help therapeutics cross the blood-brain-barrier.

Sironax's therapeutic pipeline focuses on key pathways of cellular aging, including regulated cell death, neuroinflammation, and metabolic changes. Its portfolio consists of multiple programs targeting conditions like neurodegenerative diseases, muscular weakness, and metabolic disorders. Several drug candidates, all designed and synthesized in-house, have advanced to clinical trials. Notable assets include RIPK1 (receptor-interacting serine/threonine-protein kinase 1) inhibitors, such as SIR0365, which has completed Phase 1b studies, and SIR2446, which has entered Phase 1a trials. Another candidate, SIR2501, recently completed a Phase 1 study in Australia and China for potential application in neurodegenerative diseases like ALS. Operating globally with a growing team of over 140 employees in China, the U.S., and Australia, Sironax aims to shift the treatment paradigm for a patient population currently served mostly by palliative care.